COMMUNIQUÉS West-GlobeNewswire

Integrated Cannabis Company, Inc. Enters into Licensing Agreement for Cannabidiol (CBD) Gummy Formulation

25/10/2018 - 13:30

VANCOUVER, British Columbia, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Integrated Cannabis Company, Inc. (CSE: ICAN, OTCQB: ICNAF) (“ Integrated Cannabis ”), is pleased to announce an agreement to license Cannabidiol (CBD) [...]

Ossur Hf : Interim report Q3 2018

25/10/2018 - 08:01

Announcement no. 63/2018 Interim report Q3 2018 25 October 2018 Highlights Organic sales growth of 7% in Q3 2018 and 5% in USD. Organic sales growth of 5% in 9M 2018. The prosthetics segment grew 11% organic in Q3 2018 [...]

Nexstim secures Business Finland funding for the development of wireless EMG devices

25/10/2018 - 08:01

Nexstim secures Business Finland funding for the development of wireless EMG devices The development project, to be funded by Business Finland, is part of ELASTRONICS, the largest research project in the field of [...]

Axovant Announces Dosing of First Patient in Clinical Study of AXO-Lenti-PD, a Novel Gene Therapy for Patients With Parkinson’s Disease

25/10/2018 - 08:00

Initial data from the first cohort expected in first half of 2019 BASEL, Switzerland, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON), a company developing innovative gene therapies for neurologic and [...]

Rule 2.9 Announcement

25/10/2018 - 08:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 25 October 2018 [...]

VALNEVA Receives Positive Feedback from EMA on its further Development for Lyme Disease Vaccine VLA15

25/10/2018 - 07:01

Valneva Receives Positive Feedback from EMA on its further Development for Lyme Disease Vaccine VLA15 Saint Herblain (France), October 25, 2018 - Valneva SE ("Valneva" or "the Company"), a commercial stage biotech [...]

VALNEVA reçoit un avis positif de l'EMA sur le plan de développement de son vaccin contre la maladie de Lyme

25/10/2018 - 07:01

Valneva reçoit un avis positif de l'EMA sur le plan de développement de son vaccin contre la maladie de Lyme Saint Herblain (France), 25 octobre 2018 - Valneva SE ("Valneva" ou "le Groupe"), société de biotechnologie [...]

Vistin Pharma ASA : 11 per cent revenue growth in third quarter 2018

25/10/2018 - 07:01

Oslo, Norway, 25 October 2018 Vistin Pharma delivered a revenue growth of 11 percent from NOK 46.7 million in the third quarter 2017 to NOK 51.7 million in the third quarter 2018. The underlying demand for metformin is [...]

argenx reports third quarter 2018 financial results and provides business update

25/10/2018 - 07:00

October 25, 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]

Bone Therapeutics SA: Information on the total number of voting rights and shares

25/10/2018 - 07:00

Regulated information Gosselies, Belgium, 25 October 2018, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone [...]

Bone Therapeutics SA : Information relative au nombre total de droits de vote et d’actions

25/10/2018 - 07:00

Information réglementée Gosselies, Belgique, le 25 octobre 2018, 07h00 CEST - BONE THERAPEUTICS (code Euronext Bruxelles et Paris : BOTHE), société de thérapie cellulaire osseuse qui répond à d’importants besoins [...]

MyoKardia Announces Initiative to Create Hypertrophic Cardiomyopathy Patient Community in Collaboration with 23andMe

25/10/2018 - 06:00

First-of-its-kind Digital Platform for HCM Patients Intended to Provide a Powerful Patient Resource to Improve Disease Understanding and Deepen Patient Engagement and Advocacy SOUTH SAN FRANCISCO, Calif., Oct. 25, 2018 [...]

Oncolytics Biotech® Establishes New At-The-Market Facility

25/10/2018 - 02:25

CALGARY, Alberta and SAN DIEGO, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus that turns cold [...]

LeMaitre Vascular Acquires Cardial Business of BD

24/10/2018 - 22:50

BURLINGTON, Mass., Oct. 24, 2018 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT), announced today that it has acquired the assets of Cardial, a subsidiary of BD (Becton, Dickinson & Company), located in [...]

Supernus to Host Third Quarter 2018 Earnings Conference Call

24/10/2018 - 22:30

ROCKVILLE, Md., Oct. 24, 2018 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous [...]

MyoKardia Doses First Patient in MAVA Long-Term Extension Study of Mavacamten for Hypertrophic Cardiomyopathy

24/10/2018 - 22:30

Key Remaining Study in Registration Program for oHCM Enables Assessment of Mavacamten’s Potential for Disease Modification SOUTH SAN FRANCISCO, Calif., Oct. 24, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a [...]

Align Technology Announces Third Quarter 2018 Financial Results

24/10/2018 - 22:07

Q3 revenues up 31.2% year-over-year to a record $505.3 million, and diluted EPS of $1.24 Q3 operating income up 26.8% year-over-year to $125.2 million, operating margin of 24.8% Q3 total Invisalign case shipments up 35. [...]

Sarepta Therapeutics Announces Third Quarter 2018 Financial Results and Recent Corporate Developments

24/10/2018 - 22:06

-- Third quarter 2018 EXONDYS 51® (eteplirsen) total net revenues of $78.5 million -- CAMBRIDGE, Mass., Oct. 24, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a leader in precision genetic medicine [...]

Intercept to Announce Third Quarter 2018 Financial Results on October 31, 2018

24/10/2018 - 22:05

NEW YORK, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non- [...]